Author:
Riveiro-Barciela Mar,Carballal Sabela,Díaz-González Álvaro,Mañosa Míriam,Gallego-Plazas Javier,Cubiella Joaquín,Jiménez-Fonseca Paula,Varela María,Menchén Luis,Sangro Bruno,Fernández-Montes Ana,Mesonero Francisco,Rodríguez-Gandía Miguel Ángel,Rivera Fernando,Londoño María-Carlota
Reference320 articles.
1. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance;Martins;Nat Rev Clin Oncol,2019
2. GRADE system: classification of quality of evidence and strength of recommendation;Aguayo-Albasini;Cir Esp,2014
3. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors;De Martin;JHEP Rep: Innov Hepatol,2020
4. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020
5. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review;Dougan;Gastroenterology,2021